Bevacizumab-containing treatment for relapsed or refractory Wilms tumor

Sarah Al-Jilaihawi, Filippo Spreafico, Annelies Mavinkurve-Groothuis, Jarno Drost, Daniela Perotti, Christa Koenig, Jesper Brok

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

Samenvatting

INTRODUCTION: Angiogenesis is critical for tumor growth and metastasis. Bevacizumab is an antiangiogenic drug used to treat various adult and childhood solid tumors. Its potential efficacy in Wilms tumor (WT) with poor prognosis is not established.

AREAS COVERED: The response to bevacizumab-containing regimens in relapsed or refractory WT was reviewed in available literature. Searches were conducted using PubMed, Scopus, and ClinicalTrials.gov databases. Eight papers were identified, published between 2007 and 2020, including six treatment regimens, predominantly vincristine, irinotecan, and bevacizumab (VIB) ± temozolomide (VITB). Among 16 evaluable patients, there were two complete responses, seven partial responses, five patients achieved stable disease (SD), and two patients had progressive disease. Objective responses (OR) were observed in 56% of all cases. OR or SD was observed in 89% (8/9) patients who received VIB/VITB. Bevacizumab was generally well tolerated. Related toxicities included hypertension, proteinuria, and delayed wound healing.

EXPERT OPINION: This review suggests potential effectiveness and good tolerability of bevacizumab in the setting of relapsed/refractory WT when used in combination with other drugs. Such combination therapies may serve as a bridging treatment option to other interventions and more personalized treatment options in the future; however, focused trials are needed to obtain additional evidence.

Originele taal-2Engels
Pagina's (van-tot)837-843
Aantal pagina's7
TijdschriftExpert review of anticancer therapy
Volume24
Nummer van het tijdschrift9
DOI's
StatusGepubliceerd - sep. 2024

Trefwoorden

  • Bevacizumab
  • Wilms tumor
  • relapse
  • review
  • trials

Vingerafdruk

Duik in de onderzoeksthema's van 'Bevacizumab-containing treatment for relapsed or refractory Wilms tumor'. Samen vormen ze een unieke vingerafdruk.

Citeer dit